Standard BioTools Inc.

NASDAQ:LAB

Medical - Devices

Healthcare
$0.57 +3.38%

+$0.03 today

Market cap
$225.03M
Beta
1.38
P/E (TTM)
-3.5
EPS (TTM)
-$0.24
52W Low $0.79High $1.72

Volume 0.70M

Average 2.91M

LAB Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Standard BioTools Inc.NASDAQ: LAB

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $9.84M rose 7.2% year over year, ahead of the -34.2% change in trailing-twelve-month cost of revenue. Sequentially, it fell 27.4% from the prior quarter. Over 3 fiscal years it compounded at -11.1% a year.

Context

  • Cost of revenue amounted to 50.1% of revenue in FY2025, down 1.5 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +7.2% holds above the trailing-twelve-month pace of -34.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.84M-27.4% QoQ
Last fiscal yearDec 2025
$42.79M-52.5% YoY
LTMMar 2026
$44.6M-34.2% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.2%——
1 year-52.5%——
3-year CAGR-11.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
42.79M USD
Year-over-year change
-52.5%
4-year CAGR
-8.6%

Cost of Revenue vs competitors

How LAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -34.2% is the lowest of 11, against a peer median of +12.2%.
  • Cost of revenue amounts to 51.7% of revenue for LAB, versus a peer median of 32.2%.
LAB Competitors
Cost of Revenue for LAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYSo-Young International Inc.LTM Mar 2026CN¥890.26M CNY+48.0%+25.3%54.0%
VREXVarex Imaging CorporationLTM Apr 2026$569.8M USD+3.9%-1.3%66.4%
AVNSAvanos Medical, Inc.LTM Mar 2026$368.3M USD+18.2%+6.7%51.4%
BVSBioventus Inc.LTM Mar 2026$185.67M USD-0.4%+0.8%32.2%
CTKBCytek Biosciences, Inc.LTM Mar 2026$98.61M USD+11.1%+15.4%48.3%
KIDSOrthoPediatrics Corp.LTM Mar 2026$65.51M USD+13.4%+26.3%26.9%
LABStandard BioTools Inc.LTM Mar 2026$44.6M USD-34.2%-11.1%51.7%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$42.05M USD+1.0%+16.0%20.3%
CBLLCeriBell, Inc.LTM Mar 2026$11.68M USD+28.7%+34.5%12.3%
ADCTADC Therapeutics S.A.LTM Mar 2026$7.35M USD+33.7%+32.5%9.3%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$79K USD+2.6%——
Peer median (excluding LAB) —+12.2%+16.0%32.2%

Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue130.58M97.95M106.34M174.43M85.33M
Cost of Revenue61.21M60.9M55.89M90.17M42.79M
Gross Profit69.37M37.05M50.45M84.26M42.54M
Gross Margin53.1%37.8%47.4%48.3%49.9%
Research & Development37.94M37.38M25.95M62.41M25.99M
Selling, General & Admin98.89M102.29M87.54M156.61M109.86M
Operating Expenses136.83M153.26M127.05M259.5M135.85M
Depreciation & Amortization15.57M15.03M15.18M16.86M6.98M
EBITDA(44.27M)(173.57M)(54.46M)(118.14M)(89.69M)
EBITDA Margin-33.9%-177.2%-51.2%-67.7%-105.1%
Operating Income(67.46M)(116.21M)(76.6M)(175.24M)(93.31M)
Operating Margin-51.7%-118.6%-72.0%-100.5%-109.3%
Interest Income02.23M5.57M20.2M9.18M
Interest Expense3.82M4.33M4.57M3.32M26K
Other Income / Expenses3.8M(76.72M)2.4M36.92M(3.4M)
Income Before Tax(63.66M)(192.93M)(74.2M)(138.31M)(96.7M)
Pre-Tax Margin-48.8%-197.0%-69.8%-79.3%-113.3%
Income Tax Expense(4.42M)(2.83M)452K573K(37.88M)
Net Income(59.24M)(190.1M)(74.66M)(138.89M)(74.9M)
Net Margin-45.4%-194.1%-70.2%-79.6%-87.8%
EPS (Basic)(0.78)(2.43)(0.94)(0.52)(0.20)
EPS (Diluted)(0.78)(2.43)(0.94)(0.52)(0.20)
Weighted Avg Shares75.79M78.31M79.16M352.67M381.62M
Weighted Avg Shares (Diluted)75.79M78.31M79.16M352.67M381.62M

Standard BioTools Inc.

NASDAQ:LAB

Intrinsic Alpha fair value

Locked

Current Price

$0.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.